Our stock price may be volatile; and our stockholders investment in our stock could decline in value. The market prices for our common stock and the securities of other biotechnology companies have been highly volatile and may continue to be highly volatile in the future. The following factors; in addition to other risk factors described in this section; may have a significant impact on the market price of our common stock the progress and success of our clinical trials and preclinical activities (including studies and manufacture of materials) of our product candidates conducted by us the receipt or failure to receive the additional funding necessary to conduct our business selling by large stockholders presentations of detailed clinical trial data at medical and scientific conferences and investor perception thereof announcements of technological innovations or new commercial products by our competitors or us developments concerning proprietary rights; including patents developments concerning our collaborations publicity regarding actual or potential medical results relating to products under development by our competitors or us regulatory developments in the United States and foreign countries litigation or arbitration economic and other external factors or other disaster or crisis and 24 Table of Contents period to period fluctuations in financial results.